These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1144 related articles for article (PubMed ID: 21691074)

  • 21. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
    Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L
    Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Realgar transforming solution suppresses angiogenesis and tumor growth by inhibiting VEGF receptor 2 signaling in vein endothelial cells.
    Song P; Hai Y; Wang X; Zhao L; Chen B; Cui P; Xie Q; Yu L; Li Y; Wu Z; Li H
    Arch Pharm Res; 2018 Apr; 41(4):467-480. PubMed ID: 29542005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
    Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
    Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cultivated Orostachys japonicus extract inhibits VEGF-induced angiogenesis via regulation of VEGFR2 signaling pathway in vitro and in vivo.
    Cho HD; Lee KW; Won YS; Kim JH; Seo KI
    J Ethnopharmacol; 2020 Jun; 256():112664. PubMed ID: 32045685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect.
    Tan WF; Zhang XW; Li MH; Yue JM; Chen Y; Lin LP; Ding J
    Eur J Pharmacol; 2004 Sep; 499(3):219-28. PubMed ID: 15381043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
    Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
    Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase.
    Awazu Y; Mizutani A; Nagase Y; Tsuchiya S; Nakamura K; Kakoi Y; Kitahara O; Takeuchi T; Yamasaki S; Miyamoto N; Iwata H; Miki H; Imamura S; Hori A
    Cancer Sci; 2013 Apr; 104(4):486-94. PubMed ID: 23305239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
    Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
    Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
    Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J
    Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
    McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM
    Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epoxyquinol B shows antiangiogenic and antitumor effects by inhibiting VEGFR2, EGFR, FGFR, and PDGFR.
    Kamiyama H; Kakeya H; Usui T; Nishikawa K; Shoji M; Hayashi Y; Osada H
    Oncol Res; 2008; 17(1):11-21. PubMed ID: 18488711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation.
    Kwak HJ; Park MJ; Park CM; Moon SI; Yoo DH; Lee HC; Lee SH; Kim MS; Lee HW; Shin WS; Park IC; Rhee CH; Hong SI
    Int J Cancer; 2006 Jun; 118(11):2711-20. PubMed ID: 16388516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro.
    Guo XB; Chen XJ; Tong LJ; Peng X; Huang M; Liu HC; Liu H; Ding J
    Acta Pharmacol Sin; 2015 Oct; 36(10):1266-76. PubMed ID: 26027659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway.
    Saraswati S; Kumar S; Alhaider AA
    Mol Cancer; 2013 Nov; 12():147. PubMed ID: 24261856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
    Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
    J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
    Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
    Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An-te-xiao capsule inhibits tumor growth in non-small cell lung cancer by targeting angiogenesis.
    Han L; Wang JN; Cao XQ; Sun CX; Du X
    Biomed Pharmacother; 2018 Dec; 108():941-951. PubMed ID: 30372906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
    LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
    Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.